Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANCAN Study of cannabidiol for treatment-resistant anxiety in youth
ACTRN12624000236594Phase 2Recruiting
- Sponsor
- Orygen
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in anxiety disorder comparing Cannabidiol + treatment as usual with Placebo + treatment as usual (2 arms). Primary endpoint: Change in Overall Anxiety Severity and Impairment Scale score. Started Apr 2025; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on ACTRN12624000236594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000236594.